TEL AVIV, Israel, Aug. 21, 2018 /PRNewswire/ -- The TASE analysis project was launched in 2016 in order to raise the
In order to maintain professional, independent and unbiased analysis, the companies signed an agreement with the TASE to receive the analysis services for an obligatory period of two years. The companies cannot withdraw from the project during this period. The analysis is funded by the companies surveyed with funding from the Chief Scientist and the TASE.
Summary of Highlights
On August 1st BioLineRx announced the initiation of a Phase 1/2a clinical study for AGI-134, a novel immunotherapy for the treatment of solid tumors.
On August 7th BioLineRx announced positive results for the first part of the study of its Phase 3 GENESIS Trial in stem-cell mobilization.
We increase our equity valuation of BioLineRx by 10% to $165.9M / NIS 612M, corresponding to a target price ranging between NIS 5.52 and NIS 5.84; a mean of NIS 5.67. Thus, 1 ADS (representing 1 ordinary share) is equal to $1.54.
About the company - BioLineRx Ltd. (hereinafter: "BioLineRx" or "the Company") is an Israeli clinical-stage biopharmaceutical company focused on oncology and immunology. In 2007, the company was listed on the Tel Aviv Stock Exchange. In July 2011, the company registered American Depositary Shares (ADSs) with the NASDAQ. The Company in-licenses compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.
Read the full report here.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community.
Contact us: Start the discussion
For further information, please contact:
Jacqui HolmesCorporate Communications - Frost & Sullivan, EuropeE: firstname.lastname@example.org http://www.frost.com
View original content:http://www.prnewswire.com/news-releases/frost--sullivan-publishes-quarterly-update-on-biolinerx-300700010.html
SOURCE Frost & Sullivan
Subscribe to our Free Newsletters!